924 related articles for article (PubMed ID: 16052571)
21. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study.
Lopez-Gonzalez R; Loza E; Jover JA; Benitez Del Castillo JM; Mendez R; Hernandez-Garcia C; Pato E
Scand J Rheumatol; 2009; 38(1):58-62. PubMed ID: 18991187
[TBL] [Abstract][Full Text] [Related]
22. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
23. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR
Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
[TBL] [Abstract][Full Text] [Related]
24. Azathioprine in severe uveitis of Behçet's disease.
Saadoun D; Wechsler B; Terrada C; Hajage D; Le Thi Huong D; Resche-Rigon M; Cassoux N; Le Hoang P; Amoura Z; Bodaghi B; Cacoub P
Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1733-8. PubMed ID: 20665749
[TBL] [Abstract][Full Text] [Related]
25. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease.
Takeuchi M; Asukata Y; Kawagoe T; Ito N; Nishide T; Mizuki N
Ocul Immunol Inflamm; 2012 Jun; 20(3):193-7. PubMed ID: 22486264
[TBL] [Abstract][Full Text] [Related]
26. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
27. [A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet's disease and allied conditions].
Sakane T; Mochizuki M; Inaba G; Masuda K
Ryumachi; 1995 Oct; 35(5):802-13. PubMed ID: 8594659
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy and safety of infliximab in the treatment of Behçet's disease.
Capella MJ; Foster CS
Ocul Immunol Inflamm; 2012 Jun; 20(3):198-202. PubMed ID: 22486265
[TBL] [Abstract][Full Text] [Related]
29. Uveitis in Behçet's disease.
Nussenblatt RB
Int Rev Immunol; 1997; 14(1):67-79. PubMed ID: 9203027
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
Aringer M; Graninger WB; Steiner G; Smolen JS
Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of cyclosporin-a in the treatment of Behçet's disease.
Atmaca LS; Batioğlu F
Ophthalmic Surg; 1994 May; 25(5):321-7. PubMed ID: 8058265
[TBL] [Abstract][Full Text] [Related]
32. Induction of regulatory T cells by infliximab in Behcet's disease.
Sugita S; Yamada Y; Kaneko S; Horie S; Mochizuki M
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):476-84. PubMed ID: 20861484
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of IFN-gamma-producing CD56+ T cells after combined low-dose cyclosporine/prednisone treatment in patients with Behçet's uveitis.
Ahn JK; Seo JM; Yu J; Oh FS; Chung H; Yu HG
Invest Ophthalmol Vis Sci; 2005 Jul; 46(7):2458-64. PubMed ID: 15980236
[TBL] [Abstract][Full Text] [Related]
34. Timing of recurrent uveitis in patients with Behcet's disease receiving infliximab treatment.
Yamada Y; Sugita S; Tanaka H; Kamoi K; Takase H; Mochizuki M
Br J Ophthalmol; 2011 Feb; 95(2):205-8. PubMed ID: 20542984
[TBL] [Abstract][Full Text] [Related]
35. Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis.
Sakai T; Watanabe H; Kuroyanagi K; Akiyama G; Okano K; Kohno H; Tsuneoka H
Br J Ophthalmol; 2013 Mar; 97(3):338-42. PubMed ID: 23314623
[TBL] [Abstract][Full Text] [Related]
36. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
[TBL] [Abstract][Full Text] [Related]
37. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease.
Deuter CM; Zierhut M; Möhle A; Vonthein R; Stöbiger N; Kötter I
Arthritis Rheum; 2010 Sep; 62(9):2796-805. PubMed ID: 20518075
[TBL] [Abstract][Full Text] [Related]
38. Induction of ocular Behçet's disease remission after short-term treatment with infliximab: a case series of 11 patients with a follow-up from 4 to 16 years.
Sfikakis PP; Arida A; Ladas DS; Markomichelakis N
Clin Exp Rheumatol; 2019; 37 Suppl 121(6):137-141. PubMed ID: 31856941
[TBL] [Abstract][Full Text] [Related]
39. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT
Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
[TBL] [Abstract][Full Text] [Related]
40. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease.
Abu El-Asrar AM; Abboud EB; Aldibhi H; Al-Arfaj A
Int Ophthalmol; 2005 Jun; 26(3):83-92. PubMed ID: 17031510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
